Skip to main content
. 2017 Sep 28;8(65):109723–109731. doi: 10.18632/oncotarget.21299

Table 1. Characteristics of studies included in the meta-analysis.

Authors (year) Design Population Dose of sorafenib Treatment duration Follow-up time(range) Outcomes References
Wei
Zhang (2014)
Retrospective with historical control Patients with HCC after curative resection 400 mg twice daily One month Overall survival; recurrence rate and mortality rate 12
Shen-Nien Wang (2014) Open-label, controlled phase II trail Patients with HCC after curative resection 400 mg q.d 4 months 9.5-30.2 months Recurrence rate; mortality rate 13
Lei Zhuang (2014) Retrospective with historical control Patients with HCC after curative resection 400 mg twice daily 13–44 months Overall survival; mortality rate 14
Jiang Li (2016) Retrospective with historical control BCLC stage C HCC after curative resection 200–800 mg/d One month 9–54 months Overall survival; recurrence rate; mortality rate 15
Bingfeng Chen (2016) Prospective controlled trail Patients with HCC after curative resection 400 mg twice daily 6 months 36–60 months Overall survival; recurrence rate; mortality rate 16

HCC: Hepatocellular carcinoma